Build A Bear Workshop Inc vs DexCom, Inc. — how do they compare? Build A Bear Workshop Inc trades at $36.88 (market cap $467.15M), while DexCom, Inc. trades at $89.53 (market cap $33.08B). The key difference: DexCom, Inc. is far larger — about 70.8× Build A Bear Workshop Inc's market cap, and Build A Bear Workshop Inc pays a 2.47% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| BBW | DXCM | |
|---|---|---|
Market Cap | $467.15M | $33.08B |
Sector | Consumer Cyclical | Health |
52-Week High | $75.85 | $89.53 |
52-Week Low | $29.84 | $54.84 |
Enterprise Value | $566.59M | $32.53B |
Dividend Yield | 2.47% | — |
Signals from Pluang's Aura AI — not financial advice
Build-A-Bear Workshop (BBW) trades at $36.86, up 6.19% today, with a bullish technical signal and strong analyst support. The stock exhibits attractive valuation metrics, including a P/E of 8.73 and P/S of 0.92, alongside robust profitability with a 10.48% net income margin and 35.87% ROE. Recent earnings have consistently beaten estimates, and the company maintains a debt-free balance sheet while executing a growth strategy focused on international expansion and brand partnerships.
The outlook for BBW is positive, driven by earnings momentum and a consensus price target of $62.50 implying significant upside. Key risks include near-term consumer spending volatility and execution of expansion plans, but strong fundamentals and shareholder returns via dividends support a favorable risk-reward profile for long-term investors.
DXCM trades at $84.75, up 2.08% today and near its 52-week high. The stock shows bullish technical momentum with strong earnings beats in recent quarters, including Q2 2026 EPS of $0.70 versus $0.61 expected. Revenue growth accelerated to 13% year-over-year in Q2 2026, driven by G7 system adoption and international expansion. Cash flow from operations improved to $1.44 billion in 2025, supporting financial flexibility.
Outlook remains positive with raised FY2026 guidance and 80% analyst buy ratings, though valuation multiples like P/E of 33.5 suggest premium pricing. Key risks include competitive pressures in glucose monitoring and reliance on reimbursement policies. The consensus price target of $88.65 implies modest upside from current levels.
Trailing returns across standard periods
Build-A-Bear is a global retailer specializing in customizable stuffed animals. It offers an interactive make-your-own experience where customers choose, stuff, and dress their furry friends in-store or online.
Read more on BBW →Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →